These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 8637369)

  • 21. Detecting vancomycin intermediate Staphylococcus aureus.
    Commun Dis Rep CDR Wkly; 1997 Nov; 7(47):417, 20. PubMed ID: 9401190
    [No Abstract]   [Full Text] [Related]  

  • 22. Vancomycin resistance: are there better glycopeptides coming?
    Linden PK
    Expert Rev Anti Infect Ther; 2008 Dec; 6(6):917-28. PubMed ID: 19053904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In-vitro selection of resistance of Staphylococcus aureus to teicoplanin and vancomycin.
    Watanakunakorn C
    J Antimicrob Chemother; 1990 Jan; 25(1):69-72. PubMed ID: 2138602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of the responses of staphylococci and streptococci to teicoplanin and vancomycin.
    Greenwood D; Bidgood K; Turner M
    J Antimicrob Chemother; 1987 Aug; 20(2):155-64. PubMed ID: 2959642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin.
    Harland S; Tebbs SE; Elliott TS
    J Antimicrob Chemother; 1998 Feb; 41(2):273-6. PubMed ID: 9533471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Formation and efficacy of vancomycin group glycopeptide antibiotic stereoisomers studied by capillary electrophoresis and bioaffinity mass spectrometry.
    Bonnici PJ; Damen M; Waterval JC; Heck AJ
    Anal Biochem; 2001 Mar; 290(2):292-301. PubMed ID: 11237332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Persistence of vancomycin resistance in multiple clones of Enterococcus faecium isolated from Danish broilers 15 years after the ban of avoparcin.
    Bortolaia V; Mander M; Jensen LB; Olsen JE; Guardabassi L
    Antimicrob Agents Chemother; 2015 May; 59(5):2926-9. PubMed ID: 25712360
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antimicrobial symposium. Part VIII. Glycopeptides, oxazolidinones, and lipopeptides.
    Hoffman-Roberts HL; Obritsch MD; Bronze MS; Greenfield RA
    J Okla State Med Assoc; 2007 Apr; 100(4):105-11. PubMed ID: 17476993
    [No Abstract]   [Full Text] [Related]  

  • 29. Development of in-vitro resistance to glycopeptide antibiotics: assessment in staphylococci of different species.
    Biavasco F; Giovanetti E; Montanari MP; Lupidi R; Varaldo PE
    J Antimicrob Chemother; 1991 Jan; 27(1):71-9. PubMed ID: 1828799
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In-vitro induction of resistance in coagulase-negative staphylococci to vancomycin and teicoplanin.
    Watanakunakorn C
    J Antimicrob Chemother; 1988 Sep; 22(3):321-4. PubMed ID: 2972670
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Teicoplanin-resistant coagulase-negative staphylococci.
    Arioli V; Pallanza R
    Lancet; 1987 Jan; 1(8523):39. PubMed ID: 2879112
    [No Abstract]   [Full Text] [Related]  

  • 32. Effect of banning vancomycin analogue avoparcin on vancomycin-resistant enterococci in chicken farms in Taiwan.
    Lauderdale TL; Shiau YR; Wang HY; Lai JF; Huang IW; Chen PC; Chen HY; Lai SS; Liu YF; Ho M
    Environ Microbiol; 2007 Mar; 9(3):819-23. PubMed ID: 17298380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modifications to vancomycin raise hope for combating antibiotic resistance.
    Hawkes N
    BMJ; 2017 May; 357():j2661. PubMed ID: 28572166
    [No Abstract]   [Full Text] [Related]  

  • 34. Results from Oritavancin Resistance Surveillance Programs (2011 to 2014): Clarification for Using Vancomycin as a Surrogate To Infer Oritavancin Susceptibility.
    Jones RN; Moeck G; Arhin FF; Dudley MN; Rhomberg PR; Mendes RE
    Antimicrob Agents Chemother; 2016 May; 60(5):3174-7. PubMed ID: 26926647
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus.
    Gould IM
    Int J Antimicrob Agents; 2008 Apr; 31 Suppl 2():1-9. PubMed ID: 18485997
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oritavancin retains bactericidal activity in vitro against standard and high inocula of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA).
    Arhin FF; Sarmiento I; Moeck G
    Int J Antimicrob Agents; 2013 Apr; 41(4):397-8. PubMed ID: 23374976
    [No Abstract]   [Full Text] [Related]  

  • 37. Evaluation of spontaneous resistance to glycopeptide antibiotics in staphylococcal populations.
    Biavasco F; Montanari MP; Facinelli B; Varaldo PE
    J Chemother; 1989 Jul; 1(4 Suppl):389-90. PubMed ID: 16312453
    [No Abstract]   [Full Text] [Related]  

  • 38. In-vitro susceptibility to LY333328 of vancomycin-resistant enterococci isolated from humans and animals.
    van Tiel FH; van den Bogaard TE
    J Antimicrob Chemother; 1997 Nov; 40(5):733-4. PubMed ID: 9421326
    [No Abstract]   [Full Text] [Related]  

  • 39. [Evaluation of susceptibility of methicillin resistant Staphylococcus aureus strains to vancomycin].
    Młynarczyk G; Młynarczyk A; Meisel-Mikołajczyk F
    Med Dosw Mikrobiol; 1995; 47(3-4):133-9. PubMed ID: 8833924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vancomycin-resistant enterococci (VRE) in broiler flocks 5 years after the avoparcin ban.
    Heuer OE; Pedersen K; Andersen JS; Madsen M
    Microb Drug Resist; 2002; 8(2):133-8. PubMed ID: 12118518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.